Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting?
Chronic obstructive pulmonary disease (COPD) is a predominantly smoking-related condition in which chronic progressive airways obstruction results because of inflammation that is triggered and maintained by the causative agent and enhanced during exacerbations. Inflammation is dominated by neutrophi...
Gespeichert in:
Veröffentlicht in: | Expert opinion on investigational drugs 2006-02, Vol.15 (2), p.181-184 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 184 |
---|---|
container_issue | 2 |
container_start_page | 181 |
container_title | Expert opinion on investigational drugs |
container_volume | 15 |
creator | Antoniu, Sabina A |
description | Chronic obstructive pulmonary disease (COPD) is a predominantly smoking-related condition in which chronic progressive airways obstruction results because of inflammation that is triggered and maintained by the causative agent and enhanced during exacerbations. Inflammation is dominated by neutrophils, and macrophages and their mediators. TNF-α is a proinflammatory cytokine involved in COPD pathogenesis. Treatment of the stable disease is mainly inhalatory with anticholinergics, 2 agonsists and inhaled corticosteroids being involved in various stages of the disease. Novel therapeutic agents are currently under investigation for COPD treatment and some of them target various inflammation mediators. Infliximab is a monoclonal anti-TNF-α antibody with demonstrated efficacy in other autoimmune diseases, such as Crohn s disease and rheumatoid arthritis. The current study assesses the scientific rationale for the use of infliximab in COPD patients. |
doi_str_mv | 10.1517/13543784.15.2.181 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70708192</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20388308</sourcerecordid><originalsourceid>FETCH-LOGICAL-c340t-d63d704423a0419f114a68e67153015cce25216c1ffe092e649b2a09ba0a22933</originalsourceid><addsrcrecordid>eNqFkUtP3TAQhS3Uilf7A9ggr7rLrcd24oQuqgrxkpC6adfWxJlwjZL4YjtQ_n2NgDWrmaP55kgzh7ETEBuowXwHVWtlWl3URm6ghT12CEbryjR1-6n0ZV69AAfsKKV7IaToarXPDqDRStWdOWR0s4yT_-dn7PkYInfbGBbveOhTjqvL_pH4bp3msGB85oNPhInOeA5PGIfEkc8hEk87cn4sa7644Txj9mHhGeMdZb_c_fzCPo84Jfr6Vo_Z38uLP-fX1e3vq5vzX7eVU1rkamjUYITWUqHQ0I0AGpuWGgO1ElA7R7KW0DgYRxKdpEZ3vUTR9ShQyk6pY_bt1XcXw8NKKdvZJ0fThAuFNVkjjGihkx-CUqi2VaIt4OkbuPYzDXYXy6vis33_YAF-vALl9BBn3BJOeeswkr0Pa1zKuRaEfcnLvudVlJW25KX-Aye0hoM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20388308</pqid></control><display><type>article</type><title>Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting?</title><source>MEDLINE</source><source>Taylor & Francis Journals</source><source>Taylor & Francis Medical Library - CRKN</source><creator>Antoniu, Sabina A</creator><creatorcontrib>Antoniu, Sabina A</creatorcontrib><description>Chronic obstructive pulmonary disease (COPD) is a predominantly smoking-related condition in which chronic progressive airways obstruction results because of inflammation that is triggered and maintained by the causative agent and enhanced during exacerbations. Inflammation is dominated by neutrophils, and macrophages and their mediators. TNF-α is a proinflammatory cytokine involved in COPD pathogenesis. Treatment of the stable disease is mainly inhalatory with anticholinergics, 2 agonsists and inhaled corticosteroids being involved in various stages of the disease. Novel therapeutic agents are currently under investigation for COPD treatment and some of them target various inflammation mediators. Infliximab is a monoclonal anti-TNF-α antibody with demonstrated efficacy in other autoimmune diseases, such as Crohn s disease and rheumatoid arthritis. The current study assesses the scientific rationale for the use of infliximab in COPD patients.</description><identifier>ISSN: 1354-3784</identifier><identifier>EISSN: 1744-7658</identifier><identifier>DOI: 10.1517/13543784.15.2.181</identifier><identifier>PMID: 16433597</identifier><language>eng</language><publisher>England: Ashley Publications</publisher><subject>Animals ; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage ; Antibodies, Monoclonal - administration & dosage ; Drug Delivery Systems - methods ; Humans ; Infliximab ; Pulmonary Disease, Chronic Obstructive - drug therapy ; Pulmonary Disease, Chronic Obstructive - pathology</subject><ispartof>Expert opinion on investigational drugs, 2006-02, Vol.15 (2), p.181-184</ispartof><rights>Ashley Publications 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c340t-d63d704423a0419f114a68e67153015cce25216c1ffe092e649b2a09ba0a22933</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16433597$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Antoniu, Sabina A</creatorcontrib><title>Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting?</title><title>Expert opinion on investigational drugs</title><addtitle>Expert Opin Investig Drugs</addtitle><description>Chronic obstructive pulmonary disease (COPD) is a predominantly smoking-related condition in which chronic progressive airways obstruction results because of inflammation that is triggered and maintained by the causative agent and enhanced during exacerbations. Inflammation is dominated by neutrophils, and macrophages and their mediators. TNF-α is a proinflammatory cytokine involved in COPD pathogenesis. Treatment of the stable disease is mainly inhalatory with anticholinergics, 2 agonsists and inhaled corticosteroids being involved in various stages of the disease. Novel therapeutic agents are currently under investigation for COPD treatment and some of them target various inflammation mediators. Infliximab is a monoclonal anti-TNF-α antibody with demonstrated efficacy in other autoimmune diseases, such as Crohn s disease and rheumatoid arthritis. The current study assesses the scientific rationale for the use of infliximab in COPD patients.</description><subject>Animals</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Drug Delivery Systems - methods</subject><subject>Humans</subject><subject>Infliximab</subject><subject>Pulmonary Disease, Chronic Obstructive - drug therapy</subject><subject>Pulmonary Disease, Chronic Obstructive - pathology</subject><issn>1354-3784</issn><issn>1744-7658</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtP3TAQhS3Uilf7A9ggr7rLrcd24oQuqgrxkpC6adfWxJlwjZL4YjtQ_n2NgDWrmaP55kgzh7ETEBuowXwHVWtlWl3URm6ghT12CEbryjR1-6n0ZV69AAfsKKV7IaToarXPDqDRStWdOWR0s4yT_-dn7PkYInfbGBbveOhTjqvL_pH4bp3msGB85oNPhInOeA5PGIfEkc8hEk87cn4sa7644Txj9mHhGeMdZb_c_fzCPo84Jfr6Vo_Z38uLP-fX1e3vq5vzX7eVU1rkamjUYITWUqHQ0I0AGpuWGgO1ElA7R7KW0DgYRxKdpEZ3vUTR9ShQyk6pY_bt1XcXw8NKKdvZJ0fThAuFNVkjjGihkx-CUqi2VaIt4OkbuPYzDXYXy6vis33_YAF-vALl9BBn3BJOeeswkr0Pa1zKuRaEfcnLvudVlJW25KX-Aye0hoM</recordid><startdate>200602</startdate><enddate>200602</enddate><creator>Antoniu, Sabina A</creator><general>Ashley Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200602</creationdate><title>Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting?</title><author>Antoniu, Sabina A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c340t-d63d704423a0419f114a68e67153015cce25216c1ffe092e649b2a09ba0a22933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Animals</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Drug Delivery Systems - methods</topic><topic>Humans</topic><topic>Infliximab</topic><topic>Pulmonary Disease, Chronic Obstructive - drug therapy</topic><topic>Pulmonary Disease, Chronic Obstructive - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Antoniu, Sabina A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Expert opinion on investigational drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Antoniu, Sabina A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting?</atitle><jtitle>Expert opinion on investigational drugs</jtitle><addtitle>Expert Opin Investig Drugs</addtitle><date>2006-02</date><risdate>2006</risdate><volume>15</volume><issue>2</issue><spage>181</spage><epage>184</epage><pages>181-184</pages><issn>1354-3784</issn><eissn>1744-7658</eissn><abstract>Chronic obstructive pulmonary disease (COPD) is a predominantly smoking-related condition in which chronic progressive airways obstruction results because of inflammation that is triggered and maintained by the causative agent and enhanced during exacerbations. Inflammation is dominated by neutrophils, and macrophages and their mediators. TNF-α is a proinflammatory cytokine involved in COPD pathogenesis. Treatment of the stable disease is mainly inhalatory with anticholinergics, 2 agonsists and inhaled corticosteroids being involved in various stages of the disease. Novel therapeutic agents are currently under investigation for COPD treatment and some of them target various inflammation mediators. Infliximab is a monoclonal anti-TNF-α antibody with demonstrated efficacy in other autoimmune diseases, such as Crohn s disease and rheumatoid arthritis. The current study assesses the scientific rationale for the use of infliximab in COPD patients.</abstract><cop>England</cop><pub>Ashley Publications</pub><pmid>16433597</pmid><doi>10.1517/13543784.15.2.181</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1354-3784 |
ispartof | Expert opinion on investigational drugs, 2006-02, Vol.15 (2), p.181-184 |
issn | 1354-3784 1744-7658 |
language | eng |
recordid | cdi_proquest_miscellaneous_70708192 |
source | MEDLINE; Taylor & Francis Journals; Taylor & Francis Medical Library - CRKN |
subjects | Animals Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Antibodies, Monoclonal - administration & dosage Drug Delivery Systems - methods Humans Infliximab Pulmonary Disease, Chronic Obstructive - drug therapy Pulmonary Disease, Chronic Obstructive - pathology |
title | Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A20%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Infliximab%20for%20chronic%20obstructive%20pulmonary%20disease:%20towards%20a%20more%20specific%20inflammation%20targeting?&rft.jtitle=Expert%20opinion%20on%20investigational%20drugs&rft.au=Antoniu,%20Sabina%20A&rft.date=2006-02&rft.volume=15&rft.issue=2&rft.spage=181&rft.epage=184&rft.pages=181-184&rft.issn=1354-3784&rft.eissn=1744-7658&rft_id=info:doi/10.1517/13543784.15.2.181&rft_dat=%3Cproquest_pubme%3E20388308%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20388308&rft_id=info:pmid/16433597&rfr_iscdi=true |